Health
Experimental intranasal influenza vaccine produces durable immune response – News-Medical.Net
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal…
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.
The investigational vaccine was developed by Emergent Biosolutions Inc., (Gaithersburg,…
-
Noosa News18 hours agoYoung voices shape Sunshine Coast’s future
-
Business18 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News16 hours agoAnother All-Star Cast, Another Tale of Family Chaos: The Trailer for Wes Anderson’s ‘The Phoenician Scheme’ Is Here
-
Business14 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?